Kathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School

Size: px
Start display at page:

Download "Kathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School"

Transcription

1 Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review the findings for hormone therapy and cardiovascular disease in the WHI. Present recent updates regarding impact of age and time since menopause effect modification by baseline risk follow-up findings after cessation of the randomized hormone therapy trials. Summarize consideration of cardiovascular risk prior to initiating hormone therapy for symptom control. 1

2 Heart Disease in Women Leading cause of death in women after age 40, accounting for 250, 000 deaths/year. One in 3 women will die of the disease. Heart disease begins years later in women than men. Attributed to beneficial effect of estrogen on lipids, blood vessel linings and clotting factors. Age-adjusted Death Rates for CHD, Stroke, Lung and Breast Cancer in US Women Per 100,000 Population Coronary Heart Disease Stroke Lung Cancer Breast Cancer White Females Black Females (United United States: 2004). Source: : NCHS and NHLBI. 2

3 Annual rate of first heart attack by age, sex and race. Per 1,000 Persons White Men Black Men White Women Black Women (ARIC : ) 2004). Source: NHLBI. Prevalence of CVD in Adults by Age and Sex Percent of Population Males Females (NHANES: ). Source: NCHS and NHLBI. CVD= coronary heart disease, heart failure, stroke and hypertension. 3

4 Hormone Therapy and CVD In observational studies, women who used hormone therapy were at 40-50% lower risk of CHD than never users. Hormone therapy was widely promoted and prescribed as primary prevention until the results of randomized trials failed to show benefit. Many unanswered questions remain about mechanisms and practical estimates of risk. WHI Estrogen+Progestin Trial Findings, July 2002 ( N=16,608; mean age 63 yrs; mean follow-up 5.2 yrs) Risks Benefits Coronary Heart Disease 29% Stroke 41% Pulmonary Embolism 113% Breast Cancer 26% Hip Fracture 34% Colorectal Cancer 34% Threshold Level STOPPED Early, Clear Harm Stopped 3.3 years early Adapted from: Writing Group for the Women s Health Initiative. JAMA 2002;288:

5 WHI Estrogen-Alone and Health Outcomes (N=10,739; mean age 63.6 yrs; mean follow-up 6.8 yrs) Risks Stroke 39% Null CHD (0.91) Pulm Emb (1.34) Breast Cancer (0.77) Colorectal Cancer (1.08) Total Mortality (1.04) Global Index (1.01) Benefits Hip Fracture 39% STOPPED Early Threshold Level Stopped 1 year early Source: JAMA 2004; 291: Summary of WHI hormone therapy trials: Events per 10,000 women Outcome MI Stroke VTE Breast cancer Colon cancer Fractures Dementia** E+P 7 more 8 more 18 more 6 more 6 fewer 5 fewer 23 more E alone No effect 12 more 6 more (7 fewer)* No effect 6 fewer 9 more * Borderline significance. ** For women >age 65 5

6 Key Differences Between the WHI and Observational Studies of Hormone Therapy (HT) WHI Cohorts Age at HT initiation (mean) 63 yrs 52 yrs Time since menopause (mean) >12 yrs 1-3 yrs Vasomotor symptoms Mostly Mostly + BMI (kg/m 2, mean) Duration of HT use Short Long Unanswered Questions after the WHI Are the observed associations the same for younger and older women? Is there a difference in the impact of hormones on disease risk depending on length of time since menopause? Can we predict which women are at higher cardiovascular risk? Do risks persist after stopping therapy? 6

7 Age at Initiation: WHI Results According to Age at Randomization Relative Risk of CHD by Age Group at Baseline Estrogen-alone (N=418) ( ) ( ) ( ) Estrogen+Progestin (N=348) ( ) ( ) ( ) Rossouw J, et al. JAMA 2007; 297: Age at Initiation: Relative Risk of Breast Cancer in the WHI, Stratified by Age Group Relative Risk of Breast Cancer by Age Group at Baseline E+P E-Alone Chlebowski R, et al. JAMA WHI Investigators. JAMA

8 Age at Initiation: Estrogen + Progestin Therapy and Health Outcomes in the WHI by Age Group Number of Cases per 10,000 Women per Year Age Age Age CHD Stroke VTE Total mortality Estrogen+progestin therapy Placebo VTE=venous thromboembolism Rossouw J, et al. JAMA 2007; 297: Age at Initiation: Estrogen-only Therapy and Health Outcomes in the WHI by Age Group Number of Cases per 10,000 Women per Year Age Age Age CHD Stroke VTE Total mortality Estrogen only Placebo VTE=venous thromboembolism Rossouw J, et al. JAMA 2007; 297:

9 Estrogen-alone and Coronary Artery Calcium WHI ancillary substudy : 1064 women aged 50 to 59 years at randomization Coronary artery CT was performed after 7.4 yrs of treatment and 1.3 years after the trial was completed (8.7 yrs after randomization) Mean coronary artery calcium (CAC) score was lower among women receiving estrogen (83.1) than those receiving placebo (123.1) (P=0.02 by rank test). Multivariate ORs for CAC scores of more than 0, 10 or more, and 100 or more 0.78 ( ), 0.74 ( ), and 0.69 ( ), respectively. No results for E+P. Manson JE, et al. NEJM 2007; 356: Years since Menopause: WHI Results According to Years Since Menopause Relative Risk of CHD by Years since menopause at baseline < Estrogen-alone (N=418) ( ) ( ) ( ) Estrogen+Progestin (N=348) ( ) ( ) ( ) Rossouw J, et al. JAMA 2007; 297:

10 Years since menopause: Health Outcomes by Years Since Menopause in the WHI Trials of Hormone Therapy (E+P and E-Alone) CHD <10 y Years since menopause: y 20+ y Total mortality <10 y y 20+ y Global index <10 y y 20+ y p=0.02 p=0.51 p= p values for trend. The global index is a composite outcome of CHD, stroke, PE, breast cancer, colorectal cancer, endometrial cancer (estrogen+progestin trial only), hip fracture, and mortality. Rossouw JE, et al. JAMA 2007; 297:1465. Absolute Excess Risks by Years since Menopause in the WHI Hormone Trials (Cases per 10,000 person-yrs) Outcome Years since menopause < >20 CHD * Stroke Total mortality Global index * P <0.05 compared with <10 years since menopause Global index is a composite outcome of CHD, stroke, pulmonary embolism, cancer (breast, colorectal, endometrial), hip fracture and mortality. Rossouw JE, Prentice RL, Manson JE, et al. JAMA

11 Coronary Artery Calcium in Women Randomized to Estrogen alone vs. Placebo in the WHI Coronary Artery Estrogen (0.625 CEE) Calcium Score (Intention to treat) <10 (Referent) 1.00 (Referent) ( ) > ( ) > ( ) p-value = 0.03 Manson JE, et al. NEJM 2007; 356: Baseline Risk: Effect Modification by LDL Among women in the WHI randomized trials, HT increased HDL levels and the number of HDL particles. However, while HT reduced LDL levels, there was no reduction in the number of LDL particles. In a recent substudy of 369 women in the WHI who developed CHD during the trial, and 820 controls, baseline LDL interacted with HT (both types). Women with higher LDL at baseline were at higher risk of CHD with HT use (p interaction=0.03). Hsia J, et al. Arterioscl Thromb Vasc Biol 2008; 28: Rossouw JE, et al. Arch Int Med 2008; 169:

12 Baseline CHD Risk Factors: CHD Outcomes in the WHI Trials (E+P and E-Alone) OR (95% CI) Biomarker CHD Risk P-Value LDL-Cholesterol (mg/dl) < ( ) 0.03 > ( ) Total/HDL Cholesterol Ratio < ( ) 0.01 > ( ) hs-crp (mg/dl) < ( ) 0.16 > ( ) Bray PF, et al. Am J Cardiology 2008; 101: Baseline CHD Risk Factors: Risk of CHD in the WHI Trials by Hormone Type OR (95% CI) Biomarker E+P E-alone P-Value LDL (mg/dl) < ( ) 0.71 ( ) 0.03 E+P > ( ) 1.28 ( ) 0.33 E alone Total/HDL < ( ) 0.72 ( ) 0.02 E+P > ( ) 1.33 ( ) 0.26 E alone hs-crp (mg/dl) < ( ) 0.47 ( ) 0.96 E+P > ( ) 1.88 ( ) 0.02 E alone Bray PF, et al. Am J Cardiology 2008; 101:

13 WHI Follow-up Results: Health Outcomes Three Years after Stopping E+P Relative Risks (95% CI) During Trial Post-Intervention MI 1.26 ( ) 0.99 ( ) Total CVD 1.13 ( ) 1.04 ( ) Total Cancer 1.03 ( ) 1.24 ( ) Breast CA 1.26 ( ) 1.27 ( ) Colorectal CA 0.62 ( ) 1.08 ( ) Total Fractures 0.76 ( ) 0.91 ( ) Total Mortality 0.97 ( ) 1.15 ( ) Heiss G, et al. JAMA 2008; 299:1036. Health Risks and Benefits after Stopping Randomized Treatment with Estrogen and Progestin 2.5 During trial 3-Yr Follow-up CHD MI Stroke DVT/PE All CVD Breast CA All CA 0.0 Mean follow-up of 2.8 years post-intervention. Heiss G, et al. JAMA 2008; 299:

14 WHI: CVD Risk after Cessation of HT In contrast to the risks for cancer, which remained elevated during the 3 year follow-up, the risk of CHD, stroke, DVT and PE reverted to baseline during the follow-up period. This implies that the risks of CVD with hormone therapy might be mediated by thrombotic/ hemostatic factors, rather than direct effects on atherosclerosis. 14

15 Practical Considerations: In Whom Should We Consider Using Hormone Therapy? First, assess symptoms. Significant systemic symptoms of menopause Second, evaluate contraindications and stroke risk Framingham Stroke Score <10% Third, consider overall CHD risk and years since last menstrual period. <5, 6-10, 6 >10 Practical Considerations According to Framingham CHD risk score: If very low risk (<5%) consider HT if <10 years since LMP. If low risk (5-<10%) consider HT if <5 5 years since LMP. Could consider transdermal if years since LMP. If moderate risk (10-20%) and years since LMP, could consider transdermal,, but weigh carefully. Avoid HT if more than 10 years since LMP, or if high Framingham Risk Score (>20%). 15

16 Hormone Therapy (HT) Decision-Making Flowchart 1.Significant symptoms of menopause (moderate-tosevere hot flashes, night sweats)? No No HT Yes 2. Free of contraindications to HT and no h/o CHD, stroke, or TIA? AND No increased risk of stroke (<10% by Framingham Stroke Score)? CHD Risk Over 10 Years (Framingham CHD Risk Score) 3. Assess CHD risk and years since last menstrual period Very low (<5%) Low (5% to <10%) Moderate (10% to 20%) High (more than 20%) Yes <5 HT OK HT OK HT OK (Choose transdermal) No HT Years Since Last Menstrual Period 6 to 10 HT OK HT OK (Choose transdermal) No HT No HT >10 No HT No HT No HT No HT DECISION ABOUT DURATION OF USE: continued moderate-to-severe symptoms; patient preference; weigh baseline risks of breast cancer vs osteoporosis No No HT Adapted from: J Manson and S Bassuk. In: Harrison s Principles of Internal Medicine 2008 Conclusions No data currently suggest that hormone therapy be used for disease prevention. Definitive answers about the risks and benefits of hormones in the early menopause await the results of future trials. In women with significant systemic menopausal symptoms, evaluate baseline cardiovascular risk and years since menopause to formulate a decision about using hormone therapy. 16

17 Extra slides 17

18 Framingham Risk Score CHD (10 year risk) Age Gender Smoking Total cholesterol HDL cholesterol SBP Taking meds for HTN Interactive calculator: Stroke (10 year risk) Age Gender SBP Smoking Prior CVD Atrial fibrillation LVH Taking meds for HTN Risk of Stroke in Randomized trials of Hormone Therapy Cohort WHI WHI HERS WEST HT regimen CEE/MPA CEE CEE/MPA 17beta- estradiol RR (95%CI) 1.4 ( ) 1.9) 1.4 ( ) 1.8) 1.2 ( ) 1.1 ( ) 18

19 Hormone Therapy and VTE Women s s Health Initiative CEE/MPA VTE incidence 3.1/1000 vs. 1.6/1000 on placebo. HR=2.1 ( ) Risk similar for DVT and PE CEE HR=1.4 ( ) 1.8) DVT risk significant. Absolute Excess Risks by Age in the Combined Hormone Trials of the WHI (Cases per 10,000 pers-yrs) Outcome Age (years) CHD * Stroke Total mortality * Global index * * P <0.05 compared with age years or <10 years since menopause Global index is a composite outcome of CHD, stroke, pulmonary embolism, cancer (breast, colorectal, endometrial), hip fracture and mortality. Rossouw JE, Prentice RL, Manson JE, et al. JAMA

20 Absolute Excess Risks by Age in the CEE+MPA Trial of the WHI (Cases per 10,000 pers-yrs) Outcome Age (years) CHD * Stroke Total mortality Global index * P <0.05 compared with age years or <10 years since menopause Global index is a composite outcome of CHD, stroke, pulmonary embolism, cancer (breast, colorectal, endometrial), hip fracture and mortality. Rossouw JE, Prentice RL, Manson JE, et al. JAMA Age at Initiation: Estrogen-Progestin Therapy and Health Outcomes in the WHI by Age Group Age Number of Cases per 10,000 Women per Year Age Age CHD Stroke VTE Breast Cancer Colorectal Cancer Hip Fracture Total Death Estrogen-progestin therapy Placebo VTE=venous thromboembolism 20

21 Age at Initiation: Estrogen-only Therapy and Health Outcomes in the WHI by Age Group Number of Cases per 10,000 Women per Year Age Age Age CHD Stroke VTE Breast Cancer Colorectal Cancer Hip fracture Total Death Estrogen only Placebo HT and Cerebrovascular Disease In a recent study, there was no significant increase in total ischemic volume on MRI among women on HT vs. placebo (borderline for CEE/MPA). For women older than 65, smaller brain volume and hippocampal volume were observed for women on HT than placebo. Loss particularly observed among women with cognitive deficit at baseline. Coker LH, et al. Neurology 2009; 72: Resnick SM, et al. Neurology 2009; 72:

Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice

Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice JoAnn E. Manson, MD, DrPH, FACP Chief, Division of Preventive Medicine Interim Executive Director, Connors Center Brigham and

More information

Cardiovascular Disease Risk: Pre-, Peri-, andpost-menopausal

Cardiovascular Disease Risk: Pre-, Peri-, andpost-menopausal Cardiovascular Disease Risk: Pre-, Peri-, andpost-menopausal JoAnn E. Manson, MD, DrPH, FAHA Chief, Division of Preventive Medicine Brigham and Women's Hospital Professor of Medicine i and dthe Michael

More information

Post-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018

Post-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018 Post-menopausal hormone replacement therapy Evan Klass, MD May 17, 2018 Are we really still talking about this? Are we really still talking about this? 1960-1975- estrogen prescriptions doubled. Pharma

More information

Menopausal Hormone Therapy

Menopausal Hormone Therapy V FORUM on WOMEN, HEALTH, and GENDER Madrid, October 14-15, 2008 Menopausal Hormone Therapy The Women s Health Initiative (WHI) randomized, placebo-controlled trials Marcia L. Stefanick, Ph.D. Professor

More information

Hormone therapy. Dr. med. Frank Luzuy

Hormone therapy. Dr. med. Frank Luzuy Hormone therapy Dr. med. Frank Luzuy Reasons for Initiating/Continuing HT* Menopause-Related Symptoms Osteoporosis, Bone Loss, Fracture Prevention Doctor Prescribed It, Told Me to Take It Cardiovascular

More information

Ms. Y. Outline. Updates of SERMs and Estrogen

Ms. Y. Outline. Updates of SERMs and Estrogen Ms. Y Updates of SERMs and Estrogen Steven R. Cummings, MD, FACP San Francisco Coordinating Center CPMC Research Institute and UCSF Support from Lilly, Pfizer, Berlex 55 y.o. woman with mild hypertension

More information

Menopausal hormone therapy currently has no evidence-based role for

Menopausal hormone therapy currently has no evidence-based role for IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),

More information

Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin. The WHI Investigators

Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin. The WHI Investigators Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin The WHI Investigators 1 Background: WHI Hormone Program Design YES N= 10,739 Conjugated equine estrogen

More information

Financial Conflicts of Interest

Financial Conflicts of Interest Hormone Treatment of Menopausal Women: What Are the Data Telling Us (and Not Telling Us)? S. Mitchell Harman, M.D., Ph.D. Chief, Endocrine Division Phoenix VA Health Care System Clinical Professor, Medicine

More information

SERMS, Hormone Therapy and Calcitonin

SERMS, Hormone Therapy and Calcitonin SERMS, Hormone Therapy and Calcitonin Tiffany Kim, MD Clinical Fellow VA Advanced Women s Health UCSF Endocrinology and Metabolism I have nothing to disclose Thanks to Clifford Rosen and Steven Cummings

More information

Potential dangers of hormone replacement therapy in women at high risk

Potential dangers of hormone replacement therapy in women at high risk ESC meeting, Stockholm, August 30, 16.30-18.00, 2010 Potential dangers of hormone replacement therapy in women at high risk Karin Schenck-Gustafsson MD, PhD, FESC Professor, Chief consultant Department

More information

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen

More information

Joslin Diabetes Center Primary Care Congress for Cardiometabolic Health 2013 Coronary Artery Disease in Women: Clinical Perspectives

Joslin Diabetes Center Primary Care Congress for Cardiometabolic Health 2013 Coronary Artery Disease in Women: Clinical Perspectives Primary Care Congress for Cardiometabolic Health 213 Coronary Artery Disease in : Clinical Perspectives JoAnn E. anson, D, DrPH, AHA Chief, Division of Preventive edicine Brigham and 's Hospital Professor

More information

Something has changed? The literature from 2008 to present?

Something has changed? The literature from 2008 to present? Something has changed? The literature from 2008 to present? Elina Hemminki National Institute for Health and Welfare, Helsinki, Finland Rome Oct 7, 2011: Post-menopausal hormone therapy and women's information

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Gartlehner G, Patel SV, Feltner C, et al. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: Evidence Report and Systematic Review for

More information

All medications are a double-edged sword with risks

All medications are a double-edged sword with risks Menopause: The Journal of The North American Menopause Society Vol. 14, No. 5, pp. 1/14 DOI: 10.1097/gme.0b013e31802e8508 * 2007 by The North American Menopause Society REVIEW ARTICLE Postmenopausal hormone

More information

OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc.

OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc. OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc. Napa, California IMPORTANT SAFETY INFORMATION ABOUT EVAMIST: WARNING: ENDOMETRIAL CANCER,

More information

Estrogen and progestogen therapy in postmenopausal women

Estrogen and progestogen therapy in postmenopausal women Estrogen and progestogen therapy in postmenopausal women The Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Hormone

More information

Coronary Heart Disease in Women Go Red for Women

Coronary Heart Disease in Women Go Red for Women Coronary Heart Disease in Women Go Red for Women Dr Fiona Stewart Green Lane Cardiovascular Service and National Women s Health Auckland City Hospital Auckland Heart Group Women are Different from Men

More information

Misperceptions still exist that cardiovascular disease is not a real problem for women.

Misperceptions still exist that cardiovascular disease is not a real problem for women. Management of Cardiovascular Risk Factors in the Cynthia A., MD University of California, San Diego ARHP 9/19/08 Disclosures Research support Wyeth, Lilly, Organon, Novo Nordisk, Pfizer Consultant fees

More information

HT: Where do we stand after WHI?

HT: Where do we stand after WHI? HT: Where do we stand after WHI? Hormone therapy and cardiovascular disease risk Experimental and clinical evidence indicate that hormone therapy (HT) reduces the risk of cardiovascular disease (CVD) Women

More information

THE SAFETY CHECK LIST BEFORE STARTING HT

THE SAFETY CHECK LIST BEFORE STARTING HT THE SAFETY CHECK LIST BEFORE STARTING HT This safety checklist was designed by the Endocrine Society in 2015 to minimize the chance of giving hormone therapy to women who may be negatively affected by

More information

CLINICIAN INTERVIEW CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN

CLINICIAN INTERVIEW CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN Nanette K. Wenger, MD, is a recognized authority on women and coronary heart disease. She chaired the US National Heart, Lung, and Blood Institute conference

More information

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t? Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial

More information

HRT and bone health. Management of osteoporosis and controversial issues. Delfin A. Tan, MD

HRT and bone health. Management of osteoporosis and controversial issues. Delfin A. Tan, MD Strong Bone Asia V. Osteoporosis in ASEAN (+), Danang, Vietnam, 3 August 2013 Management of osteoporosis and controversial issues HRT and bone health Delfin A. Tan, MD Section of Reproductive Endocrinology

More information

HORMONE REPLACEMENT THERAPY

HORMONE REPLACEMENT THERAPY TRIALS OF HR RUTH (Barrett- Connor et al 29 ) JULY 2006 (Country) mean ± sd, range International trial 67.5 an Placebo component in 67.5 ± 6.7 women with Raloxifene or multiple 67.5 ± 6.6 risk factors

More information

Haemostasis, thrombosis risk and hormone replacement therapy

Haemostasis, thrombosis risk and hormone replacement therapy Haemostasis, thrombosis risk and hormone replacement therapy Serge Motte Brussels 13.05.17 - MY TALK TODAY The coagulation cascade and its regulation Effects of hormone replacement therapy on haemostasis

More information

WHI Estrogen--Progestin vs. Placebo (Women with intact uterus)

WHI Estrogen--Progestin vs. Placebo (Women with intact uterus) HORMONE REPLACEMENT THERAPY In the historical period it was commonly held that estrogen had two principal benefits to postmenopausal women: 1) To alleviate the constitutional symptoms related to the climacteric

More information

BSO, HRT, and ERT. No relevant financial disclosures

BSO, HRT, and ERT. No relevant financial disclosures BSO, HRT, and ERT Jubilee Brown, MD Professor & Associate Director, Gynecologic Oncology Levine Cancer Institute at the Carolinas HealthCare System Charlotte, North Carolina No relevant financial disclosures

More information

HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer

HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer -- PART 1 -- Definitions HRT hormone replacement therapy HT genome therapy ERT estrogen replacement therapy ET estrogen EPT estrogen progesterone therapy

More information

The preferred treatment for osteoporosis

The preferred treatment for osteoporosis Alternate Options to Hormone Replacement Therapy for Osteoporosis James R. Shoemaker, DO Andrea B. Klemes, DO This presentation, developed from a symposium lecture at the 40th Annual Convention of the

More information

No relevant financial relationships

No relevant financial relationships MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu

More information

Problems in Postmenopausal Women

Problems in Postmenopausal Women Menopausal Management: Where are we in 27? Marcelle I. Cedars, M.D. Professor and Director Division of Reproductive Endocrinology and Infertility UCSF Problems in Postmenopausal Women Vasomotor symptoms

More information

Controversies in Primary Care Pros and Cons of HRT on patients with CHD

Controversies in Primary Care Pros and Cons of HRT on patients with CHD Controversies in Primary Care Pros and Cons of HRT on patients with CHD Claire Bellone MSc Clinical Nurse Specialist Menopause Nottingham Declaration Honorariums & Sponsorship from Bayer, Novonortis, Wyeth

More information

How HRT Hurts the Heart

How HRT Hurts the Heart How HRT Hurts the Heart Coronary artery disease (CAD) is a killer and recent studies have come up with evidence that HRT might have a role in increasing CAD among women. Why? Zaheer Lakhani, MD, FRCP For

More information

COMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH. Ross L. Prentice. Fred Hutchinson Cancer Research Center

COMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH. Ross L. Prentice. Fred Hutchinson Cancer Research Center COMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH Ross L. Prentice Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North, M3-A410, POB 19024, Seattle,

More information

Fasting or non fasting?

Fasting or non fasting? Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues

More information

DINE AND LEARN ENDOCRINOLOGY PEARLS. Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC

DINE AND LEARN ENDOCRINOLOGY PEARLS. Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC DINE AND LEARN ENDOCRINOLOGY PEARLS Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC OUTLINE HRT and CVD HRT and Breast Cancer Osteoporosis When to treat How long to treat for Bisphosphonates BMD

More information

WHI, HERS y otros estudios: Su significado en la clinica diária. Manuel Neves-e-Castro

WHI, HERS y otros estudios: Su significado en la clinica diária. Manuel Neves-e-Castro WHI, HERS y otros estudios: Su significado en la clinica diária III Congreso Ecuatoriano de Climaterio Menopausia y Osteoporosis por Manuel Neves-e-Castro (Lisboa-Portugal) Julho, 2003 Machala The published

More information

OVERVIEW OF MENOPAUSE

OVERVIEW OF MENOPAUSE OVERVIEW OF MENOPAUSE Nicole Budrys, MD, MPH Reproductive Endocrinology Michigan Center for Fertility and Women s Health Presented at SEMCME March 13,2019 Objectives Define menopause Etiology of menopause

More information

MENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?

MENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE? MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early

More information

WEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital

WEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital WEIGHING UP THE RISKS OF HRT V. Nicolaou Department of Endocrinology Chris Hani Baragwanath Academic Hospital Background Issues surrounding post menopausal hormonal therapy (PMHT) are complex given: Increased

More information

Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals

Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Literature Review (January 2009) Hormone Therapy for Women Women's Health

More information

OVERVIEW WOMEN S HEALTH: YEAR IN REVIEW

OVERVIEW WOMEN S HEALTH: YEAR IN REVIEW OVERVIEW WOMEN S HEALTH: YEAR IN REVIEW Judith Walsh, MD, MPH Professor of Medicine UCSF Update in Women s Health for SGIM Drs. Mary Beattie and Pam Charney Review of literature from March, 2008 through

More information

Prior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD

Prior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD Prior disclosures past 3 years Consultant for Pfizer University of Virginia received Grants/research support from TherapeuticsMD JoAnn V. Pinkerton, MD Professor of Obstetrics and Gynecology Director,

More information

2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary

2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary 2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Becky McKibben, MPH; Seth

More information

Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11

Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11 Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11 Clinical Pearl Post Women's Health Initiative Menopausal Women and Hormone Therapy by JoAnn V. Pinkerton,

More information

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial

More information

Menopause management NICE Implementation

Menopause management NICE Implementation Menopause management NICE Implementation Dr Paula Briggs Consultant in Sexual & Reproductive Health Southport and Ormskirk NHS Hospital Trust Why a NICE guideline (NG 23) Media reports about HRT have not

More information

HRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College

HRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College HRT in Perimenopausal Women Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College 1 This is the Change But the CHANGE is not a disease 2 Introduction With a marked increase in longevity, women now

More information

WHI. Hormone Therapy (HT) Trials: Estrogen + Progestin (Uterus) Estrogen-alone (No uterus) Hormone

WHI. Hormone Therapy (HT) Trials: Estrogen + Progestin (Uterus) Estrogen-alone (No uterus) Hormone WHI Therapy (HT) Trials: Estrogen + Progestin (Uterus) Estrogen-alone (No uterus) Opening Remarks; Overview of Session; Introductions Marcia L. Stefanick, PhD Principal Investigator Stanford Clinical Center

More information

Prevention of Heart Disease: The New Guidelines

Prevention of Heart Disease: The New Guidelines Prevention of Heart Disease: The New Guidelines Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California San Francisco May 18 th 2015

More information

Women s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School

Women s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Women s Health: Managing Menopause Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School Disclosures I have no conflicts of interest. Learning Objectives 1. Apply strategies to help

More information

Menopause and HRT. John Smiddy and Alistair Ledsam

Menopause and HRT. John Smiddy and Alistair Ledsam Menopause and HRT John Smiddy and Alistair Ledsam Menopause The cessation of menstruation Diagnosed retrospectively after 1 year of amenorrhoea Average age 51 in the UK Normal physiology - Menstruation

More information

AusPharm CE Hormone therapy 23/09/10. Hormone therapy

AusPharm CE Hormone therapy 23/09/10. Hormone therapy Hormone therapy Learning objectives: Assess options to address quality of life and health concerns of menopausal women Outline indications for hormone therapy Counsel women on the risks and benefits of

More information

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE

More information

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain

More information

Postmenopausal hormone therapy - cardiac disease risks and benefits

Postmenopausal hormone therapy - cardiac disease risks and benefits Postmenopausal hormone therapy - cardiac disease risks and benefits Tomi S. Mikkola, MD Helsinki University Central Hospital Department of Obstetrics and Gynecology Helsinki, Finland Disclosures Speaker/consulting

More information

Menopausal Management: What Has Changed?

Menopausal Management: What Has Changed? Menopausal Management: What Has Changed? Julia V. Johnson, M.D. Professor and Chair, OB/GYN University of Massachusetts Medical School UMass Memorial Medical Center Conflicts of Interest None Learning

More information

Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?

Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient? Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient? Donald M. Lloyd-Jones, MD, ScM, FACC, FAHA Senior Associate Dean Chair, Department of Preventive

More information

Applying Best Evidence to Menopause Management MENOPAUSE IS NOT A DISEASE. Overview. Feminine Forever. Page 1

Applying Best Evidence to Menopause Management MENOPAUSE IS NOT A DISEASE. Overview. Feminine Forever. Page 1 Applying Best Evidence to Menopause Management Judith Walsh, MD, MPH Division of General Internal Medicine Women s Health Center of Excellence UCSF Overview Natural history of menopause Hormone therapy:

More information

American Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida

American Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida The 21 st Century Paradigm Shift: Prevention Rather Than Intervention for the Treatment of Stable CHD The Economic Burden of Cardiovascular Diseases Basil Margolis MD, FACC, FRCP Director, Preventive Cardiology

More information

Applying Best Evidence to Menopause Management MENOPAUSE IS NOT A DISEASE. Overview. Feminine Forever. Page 1

Applying Best Evidence to Menopause Management MENOPAUSE IS NOT A DISEASE. Overview. Feminine Forever. Page 1 Applying Best Evidence to Menopause Management Judith Walsh, MD, MPH Division of General Internal Medicine Women s Health Center of Excellence UCSF Overview Natural history of menopause Hormone therapy:

More information

Heart Disease in Women: Is it Really Different?

Heart Disease in Women: Is it Really Different? Heart Disease in Women: Is it Really Different? Jennifer Jarbeau, MD Southcoast Physicians Group Cardiovascular Associates of RI Disclosures I have no financial interests to disclose I wish I did! Are

More information

Applying Best Evidence to Menopause Management

Applying Best Evidence to Menopause Management Applying Best Evidence to Menopause Management Judith Walsh, MD, MPH Division of General Internal Medicine Women s Health Center of Excellence UCSF Overview Natural history of menopause Hormone therapy:

More information

Current Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD

Current Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center

More information

Supplemental Table S2: Subgroup analysis for IL-6 with BMI in 3 groups

Supplemental Table S2: Subgroup analysis for IL-6 with BMI in 3 groups Supplemental Table S1: Unadjusted and Adjusted Hazard Ratios for Diabetes Associated with Baseline Factors Considered in Model 3 SMART Participants Only Unadjusted Adjusted* Baseline p-value p-value Covariate

More information

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial

More information

Problems in Postmenopausal Women. Case 1. Menopausal Management: Where are we in 2010? 10/29/2010

Problems in Postmenopausal Women. Case 1. Menopausal Management: Where are we in 2010? 10/29/2010 Menopausal Management: Where are we in 21? Marcelle I. Cedars, M.D. Professor and Director Division of Reproductive Endocrinology and Infertility UCSF Problems in Postmenopausal Women Vasomotor symptoms

More information

Conflict of Interest. Problems in Peri- Postmenopausal Women. Hormone Replacement Therapy Where are we in /27/2011

Conflict of Interest. Problems in Peri- Postmenopausal Women. Hormone Replacement Therapy Where are we in /27/2011 Hormone Replacement Therapy Where are we in 2011 Conflict of Interest Financial conflict none Research conflict Funded research: Kronos Early Estrogen Progestin Study (KEEPS) Marcelle I. Cedars, M.D. Professor

More information

The Framingham Coronary Heart Disease Risk Score

The Framingham Coronary Heart Disease Risk Score Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although

More information

Disclosures. Learning Objectives. Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease. None

Disclosures. Learning Objectives. Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease. None Effects of Hormone Therapy on the Metabolic Syndrome and Cardiovascular Disease Micol S. Rothman, MD Associate Professor of Medicine Endocrinology, Diabetes and Metabolism Clinical Director Metabolic Bone

More information

Problems in Postmenopausal Women

Problems in Postmenopausal Women Menopausal Management: Where are we in 29? Marcelle I. Cedars, M.D. Professor and Director Division of Reproductive Endocrinology and Infertility UCSF Problems in Postmenopausal Women Vasomotor symptoms

More information

Summary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene)

Summary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene) EMA/679870/2014 Summary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene) This is a summary of the risk management plan (RMP) for Duavive, which details the measures

More information

Sex, hormones and the heart

Sex, hormones and the heart Sex, hormones and the heart Dr Louise Newson BSc(Hons) MBChB(Hons) MRCP FRCGP www.menopausedoctor.co.uk #IandA2017 Declaration I have had financial relationships (lecturer, writer, member of advisory boards

More information

CVD risk assessment using risk scores in primary and secondary prevention

CVD risk assessment using risk scores in primary and secondary prevention CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities

More information

HRT & Menopause Where Do We Stand Now?

HRT & Menopause Where Do We Stand Now? HRT & Menopause Where Do We Stand Now? Mrs. SY Hussain Consultant Gynaecologist The Holly Private Hospital Spire Roding Hospital The Wellington Hospital Discussion Points Discuss Recommendations made by

More information

Placebo-Controlled Statin Trials

Placebo-Controlled Statin Trials PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of

More information

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular

More information

Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly

Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly Paul Muntner, PhD MHS Professor and Vice Chair Department of Epidemiology University of Alabama

More information

Preventing Cardiovascular Disease Stroke Primary Prevention Guidelines. John Potter Professor Ageing & Stroke Medicine University of East Anglia

Preventing Cardiovascular Disease Stroke Primary Prevention Guidelines. John Potter Professor Ageing & Stroke Medicine University of East Anglia Preventing Cardiovascular Disease Stroke Primary Prevention Guidelines John Potter Professor Ageing & Stroke Medicine University of East Anglia Preventing Cardiovascular Disease Stroke Primary Prevention

More information

WOMEN S HEALTH: A REVIEW OF THIS YEAR S MOST IMPORTANT PAPERS OVERVIEW BUT NOT. TOPICS 8/14/2009. Judith Walsh, MD, MPH Professor of Medicine UCSF

WOMEN S HEALTH: A REVIEW OF THIS YEAR S MOST IMPORTANT PAPERS OVERVIEW BUT NOT. TOPICS 8/14/2009. Judith Walsh, MD, MPH Professor of Medicine UCSF WOMEN S HEALTH: A REVIEW OF THIS YEAR S MOST IMPORTANT PAPERS Judith Walsh, MD, MPH Professor of Medicine UCSF OVERVIEW Update in Women s Health for SGIM Drs. Mary Beattie and Pam Charney Review of literature

More information

Disclosures. Prevention of Heart Disease: The New Guidelines. Summary of Talk. Four guidelines. No relevant disclosures.

Disclosures. Prevention of Heart Disease: The New Guidelines. Summary of Talk. Four guidelines. No relevant disclosures. Disclosures Prevention of Heart Disease: The New Guidelines No relevant disclosures Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California

More information

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE

More information

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest

More information

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention

More information

How would you manage Ms. Gold

How would you manage Ms. Gold How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56

More information

The Practice Committee of the American Society for Reproductive Medicine,

The Practice Committee of the American Society for Reproductive Medicine, FERTILITY AND STERILITY VOL. 81, NO. 1, JANUARY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. PRACTICE COMMITTEE Estrogen

More information

The Latest Generation of Clinical

The Latest Generation of Clinical The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform

More information

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment

More information

Status Update on the National Cardiovascular Prevention Guidelines - JNC 8, ATP 4, and Obesity 2

Status Update on the National Cardiovascular Prevention Guidelines - JNC 8, ATP 4, and Obesity 2 TABLE OF CONTENTS Status Update on the National Cardiovascular Prevention Guidelines 1 Drosperinone-Containing Oral Contraceptives and Venous Thromboembolism Risk 1-4 P&T Committee Formulary Action 5 Status

More information

SUPPLEMENTAL MATERIAL

SUPPLEMENTAL MATERIAL SUPPLEMENTAL MATERIAL Supplemental Table 1. Distribution of Participants Characteristics by Treatment Group at Baseline - The Vitamin D and calcium (CaD) Trial of the Women s Health Initiative (WHI) Study,

More information

MENOPAUSE. Women in Midlife: Menopause & Osteoporosis. Outline for Menopause. STRAW Stages of the Menopausal Transition-NAMS, /29/2012

MENOPAUSE. Women in Midlife: Menopause & Osteoporosis. Outline for Menopause. STRAW Stages of the Menopausal Transition-NAMS, /29/2012 Women in Midlife: Menopause & Osteoporosis Lisa Ward, MD, MScPH, MS UCSF CME Conference March 23rd, 2012 MENOPAUSE Outline for Menopause Definitions Summary of the Evidence Current Guidelines Management

More information

Testosterone Therapy in Men An update

Testosterone Therapy in Men An update Testosterone Therapy in Men An update SANDEEP DHINDSA Associate Professor of Medicine Director, Division of Endocrinology and Metabolism, Saint Louis University, St. Louis, MO Presenter Disclosure None

More information

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS? HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL

More information

Natural Hormones Replacement An Evidence and Practice Based Approach

Natural Hormones Replacement An Evidence and Practice Based Approach Natural Hormones Replacement An Evidence and Practice Based Approach Andres Ruiz, PharmD, MSc, FACA President/Partner Stonegate Pharmacy PRESENTED BY THE AMERICAN COLLEGE OF APOTHECARIES 2830 SUMMER OAKS

More information

5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016

5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016 Outpatient Stroke Management Sheila Smith MD May 5, 2016 1 Management of Outpatient Stroke Objectives Review blood pressure management post stroke Review antithrombotic therapy Review statin therapy Discuss

More information

For more than 50 million American women, and millions

For more than 50 million American women, and millions AHA Science Advisory Hormone Replacement Therapy and Cardiovascular Disease A Statement for Healthcare Professionals From the American Heart Association Lori Mosca, MD, PhD; Peter Collins, MD; David M.

More information

Conflict of Interest. Problems in Peri- Postmenopausal Women. Management of Menopause 10/24/2014. Financial conflict none Research conflict

Conflict of Interest. Problems in Peri- Postmenopausal Women. Management of Menopause 10/24/2014. Financial conflict none Research conflict Conflict of Interest Management of Menopause Marcelle I. Cedars, M.D. Professor and Director Division of Reproductive Endocrinology and Infertility UCSF Financial conflict none Research conflict Funded

More information

Cardiovascular Risk Reduction in Women

Cardiovascular Risk Reduction in Women Cardiovascular Risk Reduction in Women Karol E. Watson, MD, PhD Assistant Professor of Medicine/ Division of Cardiology Co-director, UCLA Program in Preventive Cardiology Director, Women s Cardiovascular

More information